018620.Kq

The company's capital structure is characterized by a debt-to-equity ratio of 1.02, indicating a relatively balanced mix of debt and equity financing. However, the company's liquidity position is assessed as medium, with a current ratio of 1.2, suggesting limited short-term liquidity cushion. The company holds cash and equivalents of KRW 13,632,415,990, but this is offset by long-term debt of KRW 31,293,619,950, resulting in a net cash position that is negative after subtracting total debt.

Profitability metrics show a return on equity of -5.76% and a return on assets of -1.63%, both of which are below the typical expectations for the pharmaceutical industry. The company reported a net loss of KRW 1,773,535,980, which contrasts with a gross profit of KRW 16,532,370,860, indicating significant operating and non-operating expenses.

The company's revenue is not segmented by geographic region or product line in the available data, so it is not possible to assess geographic or segment concentration. However, the lack of disclosed segments suggests that the company may have a relatively concentrated business model, which could increase exposure to regional or product-specific risks.

The company's growth trajectory is uncertain, as the available data does not provide forward-looking revenue guidance or outlook for the current or next fiscal year. The company's operating income of KRW 1,501,922,170 is significantly lower than its gross profit, indicating high operating expenses or challenges in cost control.

The company's risk profile includes a medium liquidity risk and a low dilution risk. The net cash position is negative after subtracting total debt, which could constrain the company's ability to fund operations or invest in growth without external financing. The dilution risk is low, as the number of shares outstanding is the same for both basic and diluted shares, indicating no significant potential for share dilution.

Recent events and filings are not detailed in the available data, so it is not possible to assess the company's recent strategic or operational developments. The company's financial performance and risk profile suggest that investors should monitor its liquidity position and operating expenses closely.